Background: The Vancouver Program initiated multidisciplinary and multimodality risk stratification to determine patients' suitability for a transfemoral (TF) minimalist peri-procedural approach, and implemented risk-stratified clinical pathways to facilitate discharge and reduce length of stay. Methods: Standardized screening was implemented to conduct multimodality assessments. Following multidisciplinary eligibility decision for TF TAVR by the Heart Team, additional risk stratification was discussed to determine individuals' appropriateness for the peri-procedural "General Anaesthesia and Transesophageal Echocardiography" ("GA/TEE") and "Awake" (e.g., local anaesthesia) protocols, and the planning requirements for standard (post-procedure day 3) and early (post-procedure day 1-2) discharge protocols. Risk-stratified clinical pathways were developed to support the patient cohorts. Results: 144 consecutive patients were accepted for TF TAVR and assigned to riskstratified protocols. The mean age was 82AE7 years, with the proportion of women ranging from 37% to 42%, and mean STS risk scores between 6.3 and 7.1 in the 4 cohorts. The overall in-hospital outcomes included 2.1% mortality, 0% myocardial infarction, 0.7% stroke, 2.1% life threatening bleeding, 0.7% new dialysis, and 4.2% conduction disturbances requiring a new permanent pacemaker. The median length of stay for all patients was 3 days (IQR 2-3), 2 days (IQR 1-3) in the Awake cohort and 2 (IQR 1-2) in the Early Discharge cohort; 95.8% of patients were discharged home. The 30-day all-cause hospital readmission rate was 11.1%, ranging from 7% and 8% in the Awake and Early Discharge cohorts respectively, to 13% in the GA/TEE and Regular Discharge cohorts; no new deaths occurred between discharge and 30 days. Conclusions: Early experience with TAVR risk stratification, individualized procedure planning and tailored clinical pathways supported by multimodality screening and multidisciplinary case selection and care results in excellent outcomes and optimized length of stay. Background: Chronic kidney injury (CKD) seems to affect survival after TAVI, but inconsistency in data exists. On the contrary, acute kidney injury (AKI) after TAVI is prevalent and more clearly associated with mortality. However, an improvement in serum creatinine is also prevalent after TAVI, possibly due to an improved renal blood flow. We analyzed the effects of an improved serum creatinine on prognosis in patients with and without CKD undergoing TAVI. Methods: All patients undergoing TAVI in our centre for whom multiple serum creatinine measurements after TAVI were available were prospectively enrolled from June 2007 to December 2013. CKD was defined as a glomerular filtration rate < 60ml/min. Serum creatinine was measured before and after TAVI. The ratio of the highest creatinine value after TAVI to before TAVI (CRR) was calculated. A CRR < 1.0 was defined as an improvement, and a CRR !1.5 as AKI, further divided according to the AKIN classification. Results: In total, TAVI was performed on 196 (mean age 82.1AE6.4, male 42%, logistic EuroSCORE 26.9AE16.6%) and 218 (mean age 79.9AE7.5, male 45%, logistic EuroSCORE 23.8AE15.1%) patients with and without CKD, respectively. In the CKD group, CRR was < 1.0, 1.0-1.5, and !1.5 in 98 (50.0%), 70 (35.7%) and 28 (14.3%) of patients, respectively. In the group with normal renal function, CRR was < 1.0, 1.0-1.5, and !1.5 in 85 (38.9%), 108 (49.5%) and 25 (11.5%) of patients, respectively. AKI was an independent predictor for early and late mortality. An improvement of renal function was a negative independent predictor for 2-year mortality in patients with CKD (HR 0.28, 95% CI 0.15 to 0.51, p< 0.001) but not for patients without CKD (HR 0.70, 95% CI 0.41 to 1.20, p¼0.19). Conclusions: The occurrence of AKI is an independent predictor for mortality after TAVI in patients with and without CKD. However, an improved renal function after TAVI predicts long-term survival only for patients with prior CKD.
TCT-743
To Background: The aim of this study was to compare the outcomes of transcatheter aortic valve implantation (TAVI) with the Medtronic CoreValve Revalvivng SystemÒ (MCV) with or without preparatory balloon aortic valvuloplasty (PBAV). Methods: From November 2007 to September 2013 all patients treated with MCV were included in this analysis. Patients were divided in 2 groups: those where PBAV was performed and those where MCV was directly implanted. PBAV was performed according to operator descretion, after consideration of patient anatomical characteristics. Outcomes were assessed according to valvular academic research consortium (VARC-2) criteria at 30 days and 1 year. Results: Of 538 patients that underwent TAVI in our center, 206 were treated with a MCV via one of the available access routes. Of those, 133 underwent PBAV, while 73 direct valve implantation. Baseline characteristics between the 2 groups were similar. At 30 days there were no significant differences in all-cause and cardiovascular mortality (3% vs. 5.5%, p ¼ 0.380; and 1.5% vs. 5.5%, p ¼ 0.105; respectively). A trend for a higher incidence of cardiac tamponade (2.4% vs. 7.8%; p ¼ 0.078) and a significantly higher rate of at least moderate peri-prosthesic aortic regurgitation (PPAR) requiring valvular balloon post-dilation (VBPD; 35.6% vs. 49.3%, p¼ 0.056) was noted amongst patients where PBAV was not performed. Conversely patients who underwent PBAV had more AKI (32.3% vs. 19.4%; p ¼ 0.049). No significant differences were observed in PPAR, post-procedural mean gradient, cerebrovascular events, and 30-day or 1-year VARC-2 composite endpoints between the 2 groups. Finally, at a median follow-up period of 429 days (IQR 208 -730), Kaplan-Meier curves reported no significant differences in long-term all-cause (17.8% vs. 23%; Log Rank p ¼ 0.210) and cardiovascular mortality (13.3% vs. 17.6%; Log Rank p ¼ 0.256). Conclusions: According to our results, direct MCV implantation is safe and effective, with outcomes comparable to MCV implantation with PBAV. However it was associated with a higher need of VBPD.
TCT-744
Does "High" implantation Of Self-Expandable prosthesis Affect Positively Short-And Long-Term Outcome Of Patients Undergoing Transcatheter Aortic Valve Implantation? Background: Transcatheter aortic valve implantation (TAVI) is an emerging treatment option for inoperable or high risk patients. Low implantation (over 8mm) has been frequently implicated with moderate or severe paravalvular aortic regurgitation (PVR). However, it has not been evaluated the effect of high implantation on the outcome of the procedure. The purpose of this study is to assess whether high implantation affects the short-and long-term outcome of the procedure. Methods: Consecutive patients who underwent TAVI were evaluated. Echocardiographic parameters were recorded before the procedure, at discharge of the patient and during one month-and one year-follow-up. Permanent pacemaker implantation (PPI), one month-as well as one year-mortality were recorded according to VARC criteria. ID was defined as the distance both from the native coronary cusp (NCC) and the left coronary cusp(LCC) to the deepest edge of the deployed bioprosthesis in the left ventricle using an offline program. The patients were separated into two groups according to the ID. Group I included all patients with normal (4-8 mm) or low implantation (>8mm) and Group II included those with high (0-4 mm) or over the annulus implantation(distance from either LCC or NCC < 0 mm). Results: One hundrend eighty six consecutive patients (81AE5.5 years, 103 males) who underwent TAVI were recorded.In Group I, peak gradientat discharge (17AE8 vs. 14AE4 mmHg, p< 0.01) and mean gradient at discharge (9AE4 vs. 7,5AE3,5 ,p¼0.02) was significantly higher comparing to Group II, while there was no difference among two groups during one month-and one year-follow up. Furthermore, the percentage of patients with need for PPI after TAVI, was significantly greater in Group I comparing to Group II (45.6% vs. 2.9% , p¼0.03). Similarly, one year-all cause mortality was higher in Group I (13,7% vs. 0%, p¼0.03) while one year-cardiovascular as well as one month-and in-hospital mortality did not differ among two groups. Conclusions: In conclusion, high implantation seems to have a positive effect on short-and long-term outcome of the procedure.
TCT-745
Feasibility and outcomes of transcatheter aortic valve implantation in high-risk patients with stenotic bicuspid aortic valves Background: Bicuspid aortic valve (BAV) is the most common congenital heart disease and may lead to aortic valve stenosis. Although Transcatheter Aortic Valve Replacement(TAVR) emerged as an alternative therapy in high-risk patients with tricuspid aortic valve stenosis, presence of a stenotic BAV is often considered a contraindication, due to its unique anatomy and increased risk of periprocedural complications. We aimed to assess the feasibility and outcomes of TAVR in high-risk patients with bicuspid aortic valve stenosis. Methods: The study is a prospective, single-centre registry of patients with BAV stenosis treated with TAVR. Periprocedural safety, hemodynamic and clinical outcome was observed during patient follow-up. Results: Of 130 high-risk patients with severe aortic stenosis who underwent TAVR from January 2009 to May 2014 in our centre, 15 (12.5%) patients had documented BAV. Patients were aged 76AE9 years (range 56-90), with mean Logistic EuroScore I of 20AE11%, all in New York Heart Association functional class III. The mean aortic valve area was 0.76AE0.36 cm2, mean gradient was 45.3AE15.1 mmHg and mean LVEF was 50.5AE12.4%. The procedure was performed using transfemoral access in 13 (87%), transaortic in 1 (6.5%) and transapical in 1 (6.5%) patient. Medtronic CoreValve prosthesis was implanted in 9 (60%) and Edwards Sapien XT in 6 (40%) patients. TAVI procedure was successful in 13 patients (87%). Major adverse events according to the second Valvular Academic Research Consortium definitions were present in 2 patients: 1 periprocedural death (Edwards Sapien XT 29) and 1 periprocedural stroke (Medtronic CoreValve 26). Importantly, both complications were related to prosthesis dislocation from the bicuspid aortic valve annulus. Postprocedural aortic valve mean gradient was 8AE2 mmHg and AVA 1.4AE0.4 cm2. After a mean follow-up of 13AE12 months (range 1-39) no further adverse events occurred. All survivors remained in NYHA class I or II. Conclusions: Our initial experience suggests TAVI using CoreValve and Sapien XT prostheses in high risk patients with stenotic bicuspid aortic valve is feasible, leading to good short term hemodynamic and clinical improvement.
TCT-746
Mechanism of Transcatheter Aortic Valve Replacement Anchoring Dmitry Levin 1 , Tamir Levi 2 , mark reisman 3 1 Seattle Science Foundation, Seattle, WA, 2 Edwards Life Sciences Corporation, Tel Aviv, Israel, 3 university of washington, Seattle, WA Background: TAVR success requires both anchoring and sealing in the native aortic valve complex. These two processes may be unique and not interdependent. Using undersized TAVR device we tested the mechanism of TAVR anchoring Methods: Five cadaveric hearts with severe aortic stenosis were imaged with CT-scanning. An annular diameter was measured, and a calcium score was assigned. The hearts were pressurized such that SAPIEN 3 (Edwards Lifesciences) valves and frames (implants) could be delivered and deployed. Two endoscopes were positioned, one at the apex and the other in the ascending aorta, to enable visibility. Depending on annulus size, an S3 valve or frame was chosen to be implanted under fluoroscopic and endoscopic guidance such that the implant would be smaller than the annulus currently recommended per Edwards instructions for use (IFU), Strings were attached at three points both at the inflow and outflow portions of the Edwards implants to pull and measure the force required to move the prosthesis. The implants were deployed at discrete inflation volume until the frame initially engaged with the native leaflets. Dimensions were measured, and pull forces were applied in both the LV and aortic directions until the implant demonstrated movement . A gauge attached to the strings, measured dislodgement forces.
Results: See table
Conclusions: High pull forces are required to displace undersized TAVR valves in the absence of annular interaction with the prosthesis indicating that: anchoring is at the native leaflet level and that anchoring and sealing may be two distinct processes.
TCT-747
Cost of transcatheter aortic valve implantation in the real-world: a single-center experience Charis Costopoulos 1 , Angela Frame 2 , Ghada Mikhail 3 , Nilesh Sutaria 4 , Ben Ariff 2 , Jon Anderson 5 , Andrew Chukwuemeka 5 , Iqbal S. Malik 5 1 Hammermsith Hospital, London, UK, 2 Hammersmith Hospital, London, United Kingdom, 3 Imperial College Healthcare Trust, London, United Kingdom, 4 Imperial College NHS Trust, London, London, 5 Imperial College NHS Trust, London, London Background: Transcatheter aortic valve intervention (TAVI) is a recognized lifesaving treatment for those who are at high risk for conventional aortic valve surgery. The financial cost of a TAVI "pathway" from the time of referral to the time of hospital discharge was assessed. Methods: Consecutive patients (n¼46) who underwent TAVI between February 2012 and December 2013 at Hammersmith Hospital, London, UK were included in this retrospective study. The analysis included costs of outpatient appointment, investigations prior to the procedure, the TAVI procedure as well as post-procedural costs including the cost of pacemaker implantation. NHS tariff costs were used for the assessment. Comparison of the costs incurred following implantation of the Edwards and CoreValve bioprostheses was also performed. 
Donor

